Following a flood at Sanofi Pasteur's Connaught Campus facility in Toronto last October, the company has issued a voluntary recall of its BCG vaccine in Canada, Australia and New Zealand. It has also halted all distribution of its BCG-based bladder cancer product ImmuCyst/TheraCys, which is manufactured in the same building and licensed in about 50 countries.
The company says it halted supply of ImmuCyst/TheraCys on 26 April, but patient advocacy websites contain posts from patients experiencing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?